Key facts
- Resilience (Blue Ash)’s last known valuation is $9.4B (Jan 2023).
- It has raised $3.3B; the latest was General Corporate Purpose ($867.4M) in Oct 2025.
- Notable investors include Mubadala Investment Company, GV, 8VC, New Enterprise Associates, Lux Capital — 27 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 27 names
- ·Watchlist + deal alerts for Resilience (Blue Ash)
- ·The full record, as it builds
Funding rounds
No funding rounds for Resilience (Blue Ash) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Resilience (Blue Ash)
Operator of a biopharmaceutical manufacturing company intended to change the way medicine is produced. The company offers various customized manufacturing capabilities to serve the requirements of biopharmaceuticals at different stages of the drug development process, from pre-clinical development to commercial supply, ensuring its clients with customized and scalable processes and facilities for complex and novel medicines.
- Sector
- Healthcare
- HQ
- Blue Ash, OH, United States
- Founded
- 2020
- Employees
- 1,298
- Website
- resilience.com/
- Ownership
- Privately Held (backing)
Resilience (Blue Ash) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Resilience (Blue Ash) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Resilience (Blue Ash) in its N-PORT filings yet. We sweep new filings monthly.